BELLEROPHON

comBinig cELLular and humoral immunE RespOnses as a vaccine strategy against staPHhylOcoccus aureus pathogeN

Coordinatore	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD    more  Organization address address: University Offices, Wellington Square city: OXFORD postcode: OX1 2JD contact info Titolo: Dr. Nome: Stephen Cognome: Conway Email: send email Telefono: +44 1865 289800 Fax: +44 1865 289801
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	7˙105˙812 €
EC contributo	5˙498˙829 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-2
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-09-01   -   2016-08-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD  Organization address address: University Offices, Wellington Square city: OXFORD postcode: OX1 2JD contact info Titolo: Dr. Nome: Stephen Cognome: Conway Email: send email Telefono: +44 1865 289800 Fax: +44 1865 289801	UK (OXFORD)	coordinator	2˙022˙378.00
2	IMAXIO SA  Organization address address: RUE SAINT ROCH 5/7 city: PARIS postcode: 75001 contact info Titolo: Mr. Nome: Alexandre Cognome: Le Vert Email: send email Telefono: +33 6 79 82 92 70 Fax: +33 4 74 26 15 78	FR (PARIS)	participant	2˙505˙885.00
3	EUROPEAN VACCINE INITIATIVE - EEIG  Organization address address: IM NEUERHEIMER FELD 307 city: Heidelberg postcode: 69120 contact info Titolo: Mr. Nome: Sten Cognome: Larsen Email: send email Telefono: 4530423159	DE (Heidelberg)	participant	518˙566.00
4	PRECLIN BIOSYSTEMS AG  Organization address address: ROUTE DE LA CORNICHE 4 city: EPALINGES postcode: 1066 contact info Titolo: Dr. Nome: Bettina Cognome: Ernst Email: send email Telefono: +41 795612794 Fax: 41216519009	CH (EPALINGES)	participant	452˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Staphylococcus aureus, including Meticillin-resistant S. aureus (MRSA), is one of the most important bacterial pathogens, causing skin, wound, and deep infections in both the community and in hospitals. Treatment is difficult and expensive and may require prolonged intravenous antibiotic therapy. Since there is no licensed vaccine by FDA or EMEA, prevention also relies heavily on antimicrobials to which antibiotic resistance is developing.

To reduce S. aureus disease burden, and antibiotic use associated with it, BELLEROPHON will design, manufacture, and assess in a Phase I clinical study a novel S. aureus vaccine candidate targeting both the cellular and humoral responses. It is designed to be protective against both MRSA and more sensitive S. aureus strains.

The project will rely on 4 key components: i) a recently discovered and highly conserved T-cell inducing antigen individually capable of eliciting substantial protection in mouse models; (ii) a secreted toxin antigen, antibodies against which reduce mortality (Hla); (iii) an innovative, proprietary and potent pro-immunogenic series of tags (IMX313 series) which can be fused to the antigens; (iv) the use of viral vectors, including an innovative and proprietary adenoviral vector (ChAdOx1) and/or new ways to use viral vectors to generate protective immunity (MVA mixed with proteins).

We will i) identify the most protective method of combining these components in a manufacturable and clinically deployable manner; ii) manufacture and perform initial human studies of the vaccine; iii) identify additional antigens which might further increase the efficacy of the initial product.

Our approach will contribute clinical safety and immunogenicity data for a novel vaccine strategy targeting one of the key bacterial pathogens in man. It will pave the way for rapid progression to phase II studies, and thence to larger phase II/III studies aiming to reduce infection.'